Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis

Autor: D. Dodick, K. Bruining, Catherine M. Dalton, W. Morrison, D. Derrington, A. Bowling, J. Adams, J. Hebert, S. Curtis, Minhua Yang, Gareth J. Barker, R. E. Kramer, J. P. Kelly, D. G. MacManus, Shôn Lewis, L. Costley, K. Bracht, E. Drexler, M. Malikowski, R. S. Murray, Clive Hawkins, K. Markopoulou, David P. Richman, William A. Sheremata, K. Nelson, M. Yeung, R. Wolintz, I. Rozentsvit, Joel Oger, Luanne M. Metz, Kathleen Healey, Jonathan L. Carter, Zahid Latif, J. Trotter, C. Mathews, C. Wallace, Jinan Al-Omaishi, Katherine Riester, Todd L. Richards, C. Webb, B. Harwick, Thomas E. Conturo, C. Gibson, E. Prenger, G. Foster, J. Forsyth, Michael Kaufman, L D Blumhardt, D. A H Cross, J. Curlis, James D. Bowen, C. Coombs, V. Orpe, Mark A. Agius, Omar Khan, C. Martinez, J. Takata, C. Graves, S. Putman, J. Scott, A. Diedrich, L. Capolino, J. Leitch, Per Soelberg Sørensen, M. Cochran, M. Buonocore, P. English, Christopher F. O'Brien, M. J. Keilson, A. Schneider, A. Miller, George Rice, Alexandros Tselis, C. Middleditch, S. Dombrowski, L. Wang, H. Oltazewska, J. Lauber, J. Heuser, H. Lew, Virginia Devonshire, M. Zvartau-Hinds, M. Burke, D. Patry, Paul O'Connor, M. Chang, Katherine A. Miszkiel, Lauren Seeberger, David W. Bates, L. Sciarra, E. Riddle, Robert P. Lisak, Michael Panzara, David Miller, R. Follmer, T. Jaspen, M. Din, T. Pepple, Christina Caon

Publikováno v: Multiple Sclerosis Journal. 11:568-572

Background: Natalizumab, a humanized monoclonal IgG4 antibody, is an a4-integrin antagonist, which inhibits the migration of inflammatory cells into the central nervous system, a key pathogenic mechanism in multiple sclerosis (MS). In a six month, ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38665639a011a220df8600c7e84283b2
https://doi.org/10.1191/1352458505ms1205oa

High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis

Autor: Jan Storek, George H. Kraft, Richard A. Nash, John F. DiPersio, Man Soo Park, Jinan Al-Omaishi, Joseph R. Zunt, Ted Gooley, Steven Z. Pavletic, Peter A. McSweeney, George E. Georges, Kate Ryan, Kenneth R. Maravilla, James D. Bowen, Keith M. Sullivan, Leona Holmberg, Harry Openshaw, C. Fred LeMaistre, Julie Sunderhaus, John R. Corboy, Rainer Storb

There were 26 patients enrolled in a pilot study of high-dose immunosuppressive therapy (HDIT) for severe multiple sclerosis (MS). Median baseline expanded disability status scale (EDSS) was 7.0 (range, 5.0-8.0). HDIT consisted of total body irradiat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e596aad3a5979aff522bb15411b7235
https://europepmc.org/articles/PMC2963562/